• December 16, 2021

    Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies

    Chicago, Dec. 16, 2021 – Paragon Biosciences has [...]

  • December 7, 2021

    PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION

    Chicago, Dec. 7, 2021 – Paragon Biosciences [...]

  • November 10, 2021

    Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome

    Statistically significant, clinically meaningful results obtained on the [...]

  • September 14, 2021

    Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder

    Current enrollment for stuttering study is at 75%; [...]

  • June 22, 2021

    Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

    Paragon Biosciences’ Portfolio Company Focuses on Areas with [...]

  • June 3, 2021

    Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award

    Dr. Chavala is co-founder of CiRC Biosciences with [...]

  • March 23, 2021

    Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

    Funding led by Paragon Biosciences, joined by Fidelity [...]

  • March 10, 2021

    CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

    Cell Therapy Platform Seeks to Restore Vision for [...]